June 12, 2022
Follow-up results of the phase 3 ASPEN trial comparing zanubrutinib with ibrutinib in patients with Waldenström macroglobulinemia were presented at 2022 ASCO.
June 10, 2022
Results from the phase 2 CRESTONE trial showed positive overall response rates in patients with solid tumors harboring NRG1 fusions treated with seribantumab monotherapy.
June 10, 2022
Results of the CHOICE-01 trial demonstrate the utility of toripalimab added to chemotherapy in advanced frontline non–small cell lung cancer at 2022 ASCO.
May 16, 2022
Superior post-scan disease upstaging in patients with recurrent prostate cancer was observed with 18F-rhPSMA-7.3 compared with conventional baseline imaging.
April 25, 2022
Treatment with several CAR T-cell products resulted in notable responses without an increase in cytokine release syndrome or neurotoxicity in large B-cell lymphoma with central nervous system involvement.
April 13, 2022
Novel BO-112 when combined with pembrolizumab may offer a new treatment option for patients with advanced melanoma and PD-1 inhibitor therapy resistance.
April 12, 2022
Ibrutinib plus venetoclax given at a fixed duration yielded favorable progression-free survival in patients with previously untreated, high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma.
March 19, 2022
Olaparib and non-platinum chemotherapy produced similar overall survival results when treating patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations.
March 19, 2022
Olaparib maintenance therapy will be investigated after receiving first-line chemotherapy for patients with BRCA1/2 wild-type advanced ovarian cancer.
March 17, 2022
At a recent conference, Robert Dreicer, MD, MS, MACP, FASCO, offered his advice regarding the use of androgen deprivation therapy in patients with metastatic castration-sensitive prostate cancer.